Want to see QUCY full AI Analyst Report?
Top Page
Quantum Cyber
(NASDAQ:QUCY)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.50
▲(29.31% Upside)
Action:Reiterated
Date:06/27/26
The score is weighed down primarily by weak financial performance (persistent losses, meaningful cash burn, and an unfavorable balance-sheet trajectory per the provided statements). Technical indicators add a modest headwind with negative MACD and sub-50 RSI, while valuation remains constrained by a negative P/E and no dividend. Corporate events provide the main offset, improving listing stability and near-term funding/strategic optionality, but do not fully neutralize the elevated financial risk.
Positive Factors
Improving gross margins
Sustained expansion of gross margin to ~73% signals materially improved unit economics and product mix. This structural margin strength creates operating leverage as revenue scales, increasing the prospect of moving toward sustainable profitability if fixed costs are controlled.
Negative Factors
Persistent cash burn
Consistent, sizable negative operating and free cash flow erodes runway and forces reliance on external funding. Structural cash burn constrains sustained R&D and commercialization investments and increases dilution or financing risk unless revenue or margins improve substantially.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving gross margins
Sustained expansion of gross margin to ~73% signals materially improved unit economics and product mix. This structural margin strength creates operating leverage as revenue scales, increasing the prospect of moving toward sustainable profitability if fixed costs are controlled.
Read all positive factors
Quantum Cyber (QUCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.74M
Dividend YieldN/A
Average Volume (3M)350.23K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.43
Shares Outstanding22,767,254
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)7.48
Price to Sales (P/S)8.93
P/FCF Ratio-0.40
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue67.86
Enterprise Value/Gross Profit67.86
Enterprise Value/Ebitda-2.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$917.75K
Quantum Cyber Business Overview & Revenue Model
Company Description
Mainz Biomed N.V. is a specialized enterprise in the field of molecular genetics, primarily focused on cancer diagnostics. The company's core mission involves developing and producing market-ready molecular genetic diagnostic solutions specificall...
How the Company Makes Money
null...
Quantum Cyber Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
24
Negative
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 286.72K | 537.08K | 893.99K | 895.48K | 529.88K | 577.35K |
| Gross Profit | 286.72K | 389.79K | 574.88K | 509.66K | 182.15K | 177.62K |
| EBITDA | -7.47M | -15.22M | -19.56M | -24.87M | -25.72M | -11.28M |
| Net Income | -8.42M | -16.21M | -21.65M | -26.30M | -26.39M | -11.69M |
Balance Sheet | ||||||
| Total Assets | 7.72M | 5.33M | 13.24M | 15.41M | 20.24M | 10.04M |
| Cash, Cash Equivalents and Short-Term Investments | 4.45M | 889.09K | 6.24M | 7.07M | 17.14M | 8.73M |
| Total Debt | 126.79K | 2.57M | 3.27M | 7.42M | 3.23M | 2.58M |
| Total Liabilities | 3.13M | 4.69M | 7.19M | 12.16M | 6.14M | 3.68M |
| Stockholders Equity | 4.59M | 641.60K | 6.05M | 3.25M | 14.10M | 6.36M |
Cash Flow | ||||||
| Free Cash Flow | -5.53M | -12.03M | -17.34M | -23.84M | -15.43M | -3.24M |
| Operating Cash Flow | -5.28M | -10.98M | -17.09M | -21.94M | -14.77M | -3.22M |
| Investing Cash Flow | -903.74K | -1.03M | -198.82K | -1.90M | -658.48K | 1.20M |
| Financing Cash Flow | 10.30M | 6.76M | 16.60M | 14.23M | 23.94M | 10.61M |
Quantum Cyber Technical Analysis
Negative
1.16
Price Trends
1.66
Negative
1.15
Positive
1.24
Positive
Market Momentum
-0.11
Positive
44.87
Neutral
14.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QUCY, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 1.66, and below the 200-day MA of 1.24, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 44.87 is Neutral, neither overbought nor oversold. The STOCH value of 14.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QUCY.
Quantum Cyber Risk Analysis
Quantum Cyber disclosed 40 risk factors in its most recent earnings report. Quantum Cyber reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Nasdaq maintains certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange, and if we are unable to continue to meet such continued listing requirements, Nasdaq may choose to delist our ordinary shares from its exchange, which may adversely affect the liquidity and trading price of our ordinary shares. Q4, 2023
2.
We are subject to cybersecurity risks to operational systems, security systems, infrastructure and personal data processed by us or third-party vendors or suppliers and any material failure, weakness, interruption, cyber event, incident or breach of security could prevent us from effectively operating our business or subject us to liability for mishandling sensitive data. Q4, 2023
Quantum Cyber Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $35.74M | -3.67 | -244.16% | ― | ― | ― | |
44 Neutral | $6.77M | -0.65 | -537.60% | ― | ― | 98.32% | |
43 Neutral | $3.81M | >-0.01 | -496.37% | ― | -87.25% | 87.10% | |
42 Neutral | $5.49M | -0.18 | -174.16% | ― | 33.26% | 49.65% |
* Healthcare Sector Average
QUCY
Quantum Cyber
1.57
0.15
10.56%
NDRA
ENDRA Life Sciences
5.33
1.91
55.85%
INBS
Intelligent Bio Solutions
2.30
-14.51
-86.34%
ISPC
iSpecimen
2.65
-35.77
-93.10%
BGLC
BioNexus Gene Lab Corp
1.95
-9.19
-82.50%
Quantum Cyber Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Quantum Cyber Licenses Quantum Photonic Tech for Defense Drones
Positive
Jun 15, 2026
On June 11, 2026, Quantum Cyber entered into an Intellectual Property License Agreement with Project LightShift granting it an exclusive worldwide license to quantum photonic array technology for quantum antenna systems in defense and national sec...
Business Operations and StrategyPrivate Placements and Financing
Quantum Cyber Ends At-The-Market Equity Sales Agreement
Neutral
Jun 5, 2026
On June 2, 2026, Quantum Cyber N.V. notified Maxim Group that it would terminate their at-the-market issuance sales agreement, originally signed in October 2025 and amended in May 2026, with the termination taking effect on June 7, 2026. Before en...
Business Operations and Strategy
Quantum Cyber Amends BP United Deal, Highlights Strategy
Positive
Jun 3, 2026
On June 1, 2026, Quantum Cyber N.V. amended its May 12, 2026 intellectual property license agreement with BP United Inc., replacing a previously contemplated exclusive supply agreement with a structure under which BP United will provide manufactur...
Delistings and Listing ChangesRegulatory Filings and Compliance
Quantum Cyber Regains Nasdaq Compliance, Stabilizing Listing Status
Positive
May 28, 2026
Quantum Cyber N.V. disclosed that on May 28, 2026 it received confirmation from Nasdaq’s Listing Qualifications Department that the company had regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares closed at or ab...
Business Operations and StrategyPrivate Placements and Financing
Quantum Cyber Completes Warrant Exercises, Strengthens Debt-Free Balance Sheet
Positive
May 26, 2026
On May 26, 2026, Quantum Cyber reported that all remaining outstanding warrants had been fully exercised, delivering gross proceeds of more than $15 million that are now on its balance sheet. As a result of these exercises, the company stated that...
Business Operations and StrategyExecutive/Board Changes
Quantum Cyber Appoints New Director to Strengthen Governance
Positive
May 18, 2026
On May 12, 2026, Quantum Cyber N.V. entered into an Advisory Agreement with Alexander Gurevich, appointing him as an independent advisor for a 12‑month term to guide strategic transactions, in exchange for 5 million restricted shares and exp...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Quantum Cyber Expands Equity Program and CFO Agreement
Positive
May 8, 2026
On May 4, 2026, Quantum Cyber N.V. amended its equity distribution agreement with Maxim Group LLC, increasing the maximum aggregate amount of ordinary shares that may be sold under the program from $10 million to $100 million, significantly expand...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder MeetingsStock Split
Quantum Cyber N.V. completes major financing and governance overhaul
Neutral
Apr 28, 2026
On February 13, 2026, Quantum Cyber entered into a $6 million private placement with investor David E. Lazar, issuing series A, B and C preferred shares on February 17, 2026 for $3 million and completing the second closing for series D and E prefe...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Quantum Cyber Divests ColoAlert IP, Refocuses on Pancreatic Screening
Positive
Apr 15, 2026
In February 2026, Quantum Cyber’s board decided to wind down its ColoAlert colorectal cancer screening business and halt development of its next-generation colorectal cancer screening candidates, terminating staff primarily dedicated to thos...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.